Nicox: NDA submitted for NCX 470 in the United States

Nicox announces that Kowa has submitted a Non-Disclosure Agreement (NDA) application to the FDA for NCX 470, an eye drop solution designed to lower intraocular pressure in patients with glaucoma or ocular hypertension. This major milestone could result in a €3 million payment to Nicox and a US launch by the end of 2027, subject to approval by mid-2027.

Based on the positive results of the Mont Blanc and Denali clinical trials, Nicox could benefit from recurring revenue with global commercialization ensured by its strategic partners, Kowa and Ocumension Therapeutics, covering various key markets. Their collaboration extends to several regions, including Asia, potentially bringing a new therapy to patients.